Eric Coldwell
Stock Analyst at Robert W. Baird
(4.70)
# 794
Out of 5,096 analysts
804
Total ratings
58.9%
Success rate
8.9%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Reiterated: Buy | $23 → $26 | $21.29 | +22.12% | 16 | Oct 30, 2026 | |
| ICLR ICON Public Limited Company | Reiterated: Buy | $194 → $249 | $211.36 | +17.81% | 72 | Oct 29, 2026 | |
| LH Labcorp Holdings | Reiterated: Buy | $352 → $396 | $361.39 | +9.58% | 75 | Oct 29, 2026 | |
| IQV IQVIA Holdings | Reiterated: Buy | $287 → $328 | $267.33 | +22.69% | 69 | Oct 27, 2026 | |
| DGX Quest Diagnostics | Reiterated: Hold | $255 → $262 | $251.82 | +4.04% | 62 | Oct 23, 2026 | |
| MEDP Medpace Holdings | Reiterated: Buy | $624 → $699 | $652.01 | +7.21% | 61 | Oct 23, 2026 | |
| COR Cencora | Reiterated: Buy | $370 → $375 | $330.84 | +13.35% | 76 | Oct 22, 2026 | |
| CRL Charles River Laboratories International | Reiterated: Buy | $291 → $334 | $359.41 | -7.07% | 72 | Sep 25, 2026 | |
| AHCO AdaptHealth | Reiterated: Buy | $10 → $9 | $5.81 | +54.91% | 43 | Sep 17, 2026 | |
| ACH Accendra Health | Downgraded: Hold | $6 → $1.5 | $0.2542 | +490.09% | 73 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $941 → $1,015 | $994.58 | +2.05% | 78 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $42 | $32.12 | +30.76% | 4 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $252 → $248 | $250.48 | -0.99% | 69 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $110 | $90.25 | n/a | 28 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $23 → $22 | $5.00 | n/a | 6 | May 9, 2014 |
Fortrea Holdings
Oct 30, 2026
Reiterated: Buy
Price Target: $23 → $26
Current: $21.29
Upside: +22.12%
ICON Public Limited Company
Oct 29, 2026
Reiterated: Buy
Price Target: $194 → $249
Current: $211.36
Upside: +17.81%
Labcorp Holdings
Oct 29, 2026
Reiterated: Buy
Price Target: $352 → $396
Current: $361.39
Upside: +9.58%
IQVIA Holdings
Oct 27, 2026
Reiterated: Buy
Price Target: $287 → $328
Current: $267.33
Upside: +22.69%
Quest Diagnostics
Oct 23, 2026
Reiterated: Hold
Price Target: $255 → $262
Current: $251.82
Upside: +4.04%
Medpace Holdings
Oct 23, 2026
Reiterated: Buy
Price Target: $624 → $699
Current: $652.01
Upside: +7.21%
Cencora
Oct 22, 2026
Reiterated: Buy
Price Target: $370 → $375
Current: $330.84
Upside: +13.35%
Charles River Laboratories International
Sep 25, 2026
Reiterated: Buy
Price Target: $291 → $334
Current: $359.41
Upside: -7.07%
AdaptHealth
Sep 17, 2026
Reiterated: Buy
Price Target: $10 → $9
Current: $5.81
Upside: +54.91%
Accendra Health
Aug 11, 2026
Downgraded: Hold
Price Target: $6 → $1.5
Current: $0.2542
Upside: +490.09%
Aug 6, 2026
Reiterated: Buy
Price Target: $941 → $1,015
Current: $994.58
Upside: +2.05%
Aug 6, 2026
Reiterated: Buy
Price Target: $45 → $42
Current: $32.12
Upside: +30.76%
May 1, 2026
Reiterated: Buy
Price Target: $252 → $248
Current: $250.48
Upside: -0.99%
Apr 18, 2022
Reiterated: Hold
Price Target: $110
Current: $90.25
Upside: n/a
May 9, 2014
Rated: Buy
Price Target: $23 → $22
Current: $5.00
Upside: n/a